221 related articles for article (PubMed ID: 34820593)
61. From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis.
Andreatos N; Ronnekleiv-Kelly S; Margonis GA; Sasaki K; Gani F; Amini N; Wilson A; Pawlik TM
Surg Oncol; 2016 Sep; 25(3):332-8. PubMed ID: 27566041
[TBL] [Abstract][Full Text] [Related]
62. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.
Spindler KL; Pallisgaard N; Andersen RF; Brandslund I; Jakobsen A
PLoS One; 2015; 10(4):e0108247. PubMed ID: 25875772
[TBL] [Abstract][Full Text] [Related]
63. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.
Vincenzi B; Cremolini C; Sartore-Bianchi A; Russo A; Mannavola F; Perrone G; Pantano F; Loupakis F; Rossini D; Ongaro E; Bonazzina E; Dell'Aquila E; Imperatori M; Zoccoli A; Bronte G; De Maglio G; Fontanini G; Natoli C; Falcone A; Santini D; Onetti-Muda A; Siena S; Tonini G; Aprile G
Oncotarget; 2015 Oct; 6(31):31604-12. PubMed ID: 26384309
[TBL] [Abstract][Full Text] [Related]
64. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
[TBL] [Abstract][Full Text] [Related]
65. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
66. Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients.
Kodaz H; Erdogan B; Hacibekiroglu I; Turkmen E; Tozkir H; Albayrak D; Uzunoglu S; Cicin I
Hepatogastroenterology; 2015 Jun; 62(140):876-9. PubMed ID: 26902020
[TBL] [Abstract][Full Text] [Related]
67. Kras-mutation influences outcomes for palliative primary tumor resection in advanced colorectal cancer-a Turkish Oncology Group study.
Korkmaz L; Coşkun HŞ; Dane F; Karabulut B; Karaağaç M; Çabuk D; Karabulut S; Aykan NF; Doruk H; Avcı N; Turhal NS; Artaç M
Surg Oncol; 2018 Sep; 27(3):485-489. PubMed ID: 30217306
[TBL] [Abstract][Full Text] [Related]
68. Integrating
Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
[TBL] [Abstract][Full Text] [Related]
69. The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer.
Huang CW; Tsai HL; Chen YT; Huang CM; Ma CJ; Lu CY; Kuo CH; Wu DC; Chai CY; Wang JY
BMC Cancer; 2013 Dec; 13():599. PubMed ID: 24330663
[TBL] [Abstract][Full Text] [Related]
70. Correlation between RAS Test Results and Prognosis of Metastatic Colorectal Cancer Patients: a Report from Western Iran.
Payandeh M; Shazad B; Sadeghi M; Shahbazi M
Asian Pac J Cancer Prev; 2016; 17(4):1729-32. PubMed ID: 27221845
[TBL] [Abstract][Full Text] [Related]
71. KRAS and NRAS mutational gene profile of metastatic colorectal cancer patients in Jordan.
Awidi M; Ababneh N; Shomaf M; Al Fararjeh F; Owaidi L; AlKhatib M; Al Tarawneh B; Awidi A
PLoS One; 2019; 14(12):e0226473. PubMed ID: 31881025
[TBL] [Abstract][Full Text] [Related]
72. Genomic and biological characterization of exon 4 KRAS mutations in human cancer.
Janakiraman M; Vakiani E; Zeng Z; Pratilas CA; Taylor BS; Chitale D; Halilovic E; Wilson M; Huberman K; Ricarte Filho JC; Persaud Y; Levine DA; Fagin JA; Jhanwar SC; Mariadason JM; Lash A; Ladanyi M; Saltz LB; Heguy A; Paty PB; Solit DB
Cancer Res; 2010 Jul; 70(14):5901-11. PubMed ID: 20570890
[TBL] [Abstract][Full Text] [Related]
73. Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations.
Cercek A; Braghiroli MI; Chou JF; Hechtman JF; Kemeny N; Saltz L; Capanu M; Yaeger R
Clin Cancer Res; 2017 Aug; 23(16):4753-4760. PubMed ID: 28446505
[No Abstract] [Full Text] [Related]
74. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
Modest DP; Ricard I; Heinemann V; Hegewisch-Becker S; Schmiegel W; Porschen R; Stintzing S; Graeven U; Arnold D; von Weikersthal LF; Giessen-Jung C; Stahler A; Schmoll HJ; Jung A; Kirchner T; Tannapfel A; Reinacher-Schick A
Ann Oncol; 2016 Sep; 27(9):1746-53. PubMed ID: 27358379
[TBL] [Abstract][Full Text] [Related]
75. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
76. The association of KRAS mutation with primary tumor location and survival in patients undergoing resection of colorectal cancers and synchronous liver metastases.
Allievi N; Goffredo P; Utria AF; Pisano M; Poiasina E; Lucianetti A; Zhou P; Hassan I
Chin Clin Oncol; 2019 Oct; 8(5):46. PubMed ID: 31500429
[TBL] [Abstract][Full Text] [Related]
77. Age-dependent prognostic value of
Ozer M; Goksu SY; Sanford NN; Ahn C; Beg MS; Ali Kazmi SM
Future Oncol; 2021 Dec; 17(35):4883-4893. PubMed ID: 34758634
[No Abstract] [Full Text] [Related]
78. Comprehensive Clinical and Molecular Characterization of
Henry JT; Coker O; Chowdhury S; Shen JP; Morris VK; Dasari A; Raghav K; Nusrat M; Kee B; Parseghian C; Pant S; Jeyakumar N; Zhu L; Nishioka Y; Fogelman D; Wolff RA; Hong D; Overman MJ; Vauthey J; Kopetz S; Johnson B
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250391
[TBL] [Abstract][Full Text] [Related]
79. KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease.
Tessitore A; Bruera G; Mastroiaco V; Cannita K; Cortellini A; Cocciolone V; Dal Mas A; Calvisi G; Zazzeroni F; Ficorella C; Ricevuto E; Alesse E
Hum Pathol; 2018 Apr; 74():178-182. PubMed ID: 29409955
[TBL] [Abstract][Full Text] [Related]
80. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
